NIH Blueprint Initiative: Tools for Germline Gene Editing in the Nervous System
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The NIH Blueprint initiative, managed by the National Institutes of Health under the Department of Health and Human Services, focuses on advancing the development and application of germline and somatic transgenic and gene-editing tools. The primary goal is to model human brain anatomy, circuitry, cognition, behavior, and lifespan to better understand brain function and complex diseases, such as schizophrenia and autism spectrum disorders. This effort involves integrating New Approach Methodologies with other experimental systems, including the use of marmoset gene-editing infrastructure, to facilitate cross-species comparisons and validate human-derived models. This forecast opportunity, identified under NAICS code 541714, emphasizes the necessity of using and justifying appropriate models for research into neuroanatomy and behavioral phenotyping. The initiative is supported by grant authorities 42 U.S.C 241 and 284, with administrative coordination handled by the NIDA GED Program Staff.
General Info
Estimated contract value
Up to $1,200,000Place of Performance
Not specifiedSet-Aside
Documents
0No documents available
Documents will appear here when they are available.
AI Contract Breakdown
Uniform Contract FormatNo documents to break down
The breakdown needs solicitation documents. None were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
The NIH Blueprint (a consortium of NIH Institutes that support neuroscience research) seeks to advance its mission by supporting the development, optimization, validation, and application of germline and somatic transgenic and gene-editing approaches in experimental systems modeling key features of human brain anatomy, circuitry, cognition, behavior, and lifespan. This initiative will build on the previously supported marmoset gene-editing infrastructure, by integrating New Approach Methodologies (NAMs) with other models, to advance understanding of human brain function and disease, including human-derived NAMs for cross-species comparisons across development. Many mechanisms of complex conditions, such as autism spectrum disorders, schizophrenia, and other behavioral/developmental disorders, cannot yet be captured in NAMs and are therefore high priorities for research investment to accelerate development and validation of human-derived NAMs. Appropriate models should be used and clearly justified as necessary for questions involving neuroanatomy, circuit function, cognition, behavior, or lifespan phenotyping related to human brain disease and function. Grant authorities are as follows: 42 U.S.C 241 and 284.
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Health And Human Services → National Institutes Of Health
Same awarding agency
Prepare for this forecast
Research this forecast and prepare for the solicitation
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
